All the news Showing 10 of 82 articles from: Protease inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV Achillion press release / 10 June 2014 Why Merck Just Spent $4 Billion On New Drugs For Hepatitis C Forbes / 09 June 2014 DDW 2014: Some Negative Predictive Factors Do Not Impair Response to Faldaprevir HIVandhepatitis.com / 28 May 2014 OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection Reuters / 16 May 2014 AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C AbbVie press release / 23 April 2014 Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection Merck press release / 11 April 2014 Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA for the Treatment of Hepatitis C Bristol-Myers Squibb press release / 07 April 2014 Two phase III trials evaluating once-daily simeprevir and sofosbuvir in hepatitis C infected patients have been initiated Medivir press release / 02 April 2014 CHMP summary of opinion: simeprevir (Olysio) European Medicines Agency / 24 March 2014 Simeprevir receives positive CHMP opinion for the treatment of adults with chronic hepatitis C in the European Union Medivir press release / 21 March 2014 ← Prev12345...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive